Mylan CEO Heather Bresch is expected to refuse to lower the $600 price of the allergy drug EpiPen at a congressional hearing Wednesday.

Bresch is scheduled to appear before the House Oversight and Government Reform Committee to address concerns over a price increase of 400 percent for the life-saving allergy treatment. However, her opening statement does not include any promises of lowering the price or providing more discounts beyond what Mylan has already announced.